{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:21:13Z","timestamp":1778631673552,"version":"3.51.4"},"reference-count":16,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[1998,7,1]],"date-time":"1998-07-01T00:00:00Z","timestamp":899251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[1998,7]]},"abstract":"<jats:p> Studies in vitro indicate that the antidepressant drug, venlafaxine (VEN), inhibits the reuptake of both serotonin (5-hydroxytryptamine, 5-HT) and noradrenaline (NA) but has little activity on other neurotransmitter receptors. There are, however, few studies on the effects of VEN on monoamine neurotransmission in vivo. In the present study we examined the effect of VEN treatment on the melatonin content of the rat pineal gland because the synthesis of melatonin is regulated by the release of NA onto pinealocyte \u03b2-adrenoceptors. Acute treatment with higher doses (15 mg\/kg) of VEN significantly increased pineal melatonin and NA but this effect was attenuated by subchronic treatment. These data are consistent with in vitro data suggesting that VEN increases NA neurotransmission at higher doses and that repeated treatment can desensitize pinealocyte \u03b2-adrenoceptors. <\/jats:p>","DOI":"10.1177\/026988119801200407","type":"journal-article","created":{"date-parts":[[2007,3,18]],"date-time":"2007-03-18T03:45:17Z","timestamp":1174189517000},"page":"371-374","source":"Crossref","is-referenced-by-count":9,"title":["Effect of venlafaxine on pineal melatonin and noradrenaline in the male rat"],"prefix":"10.1177","volume":"12","author":[{"given":"M.","family":"Franklin","sequence":"first","affiliation":[{"name":"University of Oxford Department of Psychiatry, Warneford Hospital, Oxford OX3 7JX, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.M.","family":"Clement","sequence":"additional","affiliation":[{"name":"University of Oxford Department of Psychiatry, Warneford Hospital, Oxford OX3 7JX, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Campling","sequence":"additional","affiliation":[{"name":"University of Oxford Department of Psychiatry, Warneford Hospital, Oxford OX3 7JX, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.J.","family":"Cowen","sequence":"additional","affiliation":[{"name":"University of Oxford Department of Psychiatry, Warneford Hospital, Oxford OX3 7JX, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1998,7,1]]},"reference":[{"key":"atypb1","unstructured":"Burns TG, Brown G.M. (1985) The effects of acute and chronic desmethylimmipramine treatment on pineal and serum melatonin and N-acetylserotonin. In Brown G M, Wainwright SD (eds), The pineal gland: endocrine aspects. Pergamon Press, Oxford, pp. 25-30"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(97)00524-0"},{"key":"atypb3","volume-title":"The effect of antidepressant treatment on pineal \u03b2-adrenoceptor function and on 5-HT-mediated behaviours in the rat","author":"Cowen PJ","year":"1984"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1983.tb09367.x"},{"key":"atypb5","unstructured":"Demisch L., Gebhart P., Yaga K., Reiter R.J. (1991) Pineal 5-HT metabolism and mechanisms of control of 5-HT N-acetyltransferase activity. In Advances in pineal research, Vol. 6. Libbey, London, p. 85"},{"key":"atypb6","first-page":"184","volume":"9","author":"Deguchi T.","year":"1973","journal-title":"Molec Pharmac"},{"key":"atypb7","volume-title":"Serotonin-noradrenaline reuptake inhibitors (SNRIs); a new horizon in antidepressant therapy","author":"de Montigny C.","year":"1995"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1126\/science.168.3934.979"},{"key":"atypb9","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(79)90100-0"},{"key":"atypb10","first-page":"261","volume":"10","author":"Moyer JA","year":"1984","journal-title":"Soc Neurosci Abstr"},{"key":"atypb11","volume-title":"The preclinical pharmacological profile of venlafaxine: a novel antidepressant agent","author":"Moyer JA","year":"1992"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(86)90769-0"},{"key":"atypb13","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.430230210"},{"key":"atypb14","doi-asserted-by":"publisher","DOI":"10.1007\/BF00443424"},{"key":"atypb15","first-page":"6","volume":"55","author":"Preskorn S.H.","year":"1994","journal-title":"J Clin Psychiat"},{"key":"atypb16","volume-title":"Pharmaceutical profile of venlafaxine","author":"Preskorn S.H.","year":"1995"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/026988119801200407","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/026988119801200407","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T18:58:50Z","timestamp":1741028330000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/026988119801200407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,7]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1998,7]]}},"alternative-id":["10.1177\/026988119801200407"],"URL":"https:\/\/doi.org\/10.1177\/026988119801200407","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,7]]}}}